MedTrace Logo

Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer

NCT02454140 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-09-12

Study results available
· View outcomes & findings →

Summary

This study is to determine the maximum tolerated dose (MTD) of five fraction stereotactic radiotherapy (SBRT) in pancreatic cancer.

Conditions

Interventions

RADIATION

SBRT

Fixed five-fraction stereotactic radiotherapy

Sponsors & Collaborators

Principal Investigators

  • James D Murphy, MD · University of California, San Diego

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-20
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02454140 on ClinicalTrials.gov